End-of-day quote
Shanghai S.E.
23:00:00 15/07/2024 BST
|
5-day change
|
1st Jan Change
|
16.42
CNY
|
+0.06%
|
|
+1.73%
|
-15.79%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,959
|
6,339
|
6,268
|
4,845
|
4,080
|
-
|
-
|
Enterprise Value (EV)
1 |
7,959
|
6,339
|
6,268
|
4,845
|
4,080
|
4,080
|
4,080
|
P/E ratio
|
61.5
x
|
33.9
x
|
33
x
|
52.7
x
|
27.8
x
|
21.6
x
|
15.8
x
|
Yield
|
0.45%
|
0.59%
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
20.4
x
|
10.7
x
|
9.66
x
|
10.5
x
|
6.69
x
|
5.36
x
|
3.96
x
|
EV / Revenue
|
20.4
x
|
10.7
x
|
9.66
x
|
10.5
x
|
6.69
x
|
5.36
x
|
3.96
x
|
EV / EBITDA
|
53,145,363
x
|
27,576,547
x
|
24,137,698
x
|
28,401,613
x
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
5.19
x
|
3.76
x
|
3.41
x
|
2.54
x
|
1.99
x
|
1.85
x
|
1.66
x
|
Nbr of stocks (in thousands)
|
248,454
|
248,454
|
248,454
|
248,454
|
248,454
|
-
|
-
|
Reference price
2 |
32.03
|
25.51
|
25.23
|
19.50
|
16.42
|
16.42
|
16.42
|
Announcement Date
|
02/02/21
|
21/02/22
|
21/02/23
|
23/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
390.4
|
593.4
|
649.2
|
460.7
|
610
|
761.5
|
1,030
|
EBITDA
|
149.8
|
229.9
|
259.7
|
170.6
|
-
|
-
|
-
|
EBIT
1 |
130.4
|
204
|
229.1
|
117.3
|
176.5
|
236.5
|
333
|
Operating Margin
|
33.39%
|
34.38%
|
35.29%
|
25.47%
|
28.93%
|
31.06%
|
32.33%
|
Earnings before Tax (EBT)
1 |
136.9
|
217.3
|
239.5
|
63.8
|
198
|
259
|
348
|
Net income
1 |
118.6
|
186.4
|
190.8
|
129.9
|
146
|
190
|
259
|
Net margin
|
30.37%
|
31.41%
|
29.39%
|
28.2%
|
23.93%
|
24.95%
|
25.15%
|
EPS
2 |
0.5207
|
0.7521
|
0.7636
|
0.3700
|
0.5900
|
0.7600
|
1.040
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
0.1438
|
0.1504
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
02/02/21
|
21/02/22
|
21/02/23
|
23/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
10.3%
|
11.6%
|
10.8%
|
4.87%
|
6.85%
|
8.3%
|
10.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
6.170
|
6.790
|
7.400
|
7.690
|
8.260
|
8.870
|
9.870
|
Cash Flow per Share
2 |
0.3100
|
0.5800
|
0.6300
|
1.080
|
0.4900
|
0.7000
|
1.340
|
Capex
1 |
30.5
|
91.3
|
138
|
25.8
|
510
|
478
|
-
|
Capex / Sales
|
7.8%
|
15.39%
|
21.29%
|
5.6%
|
83.61%
|
62.77%
|
-
|
Announcement Date
|
02/02/21
|
21/02/22
|
21/02/23
|
23/02/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -15.79% | 562M | | +75.69% | 12.57B | | -21.78% | 7.43B | | -6.25% | 5.79B | | +8.16% | 5.09B | | -17.37% | 4.78B | | +16.22% | 4.2B | | -12.50% | 4.13B | | -10.69% | 3.19B | | -1.98% | 2B |
Medical Equipment
|